TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04511637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939, Xarelto) in ODT form
Description: 15 mg as 1 x 15 mg orally disintegrating tablet (ODT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939, Xarelto) in ODT form
Description: 15 mg as 1 x 15 mg orally disintegrating tablet (ODT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939, Xarelto) in ODT form
Description: 15 mg as 1 x 15 mg orally disintegrating tablet (ODT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939, Xarelto) in ODT form
Description: 15 mg as 1 x 15 mg orally disintegrating tablet (ODT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form
Description: 15 mg as 1 x 15 mg film-coated tablet
Study: NCT01923311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVG
Description: Tablet (s) or tablet (s) for oral suspension (if unable to swallow) will be administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVG
Description: Tablet (s) or tablet (s) for oral suspension (if unable to swallow) will be administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background regimen
Description: Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants \< 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background regimen
Description: Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants \< 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background regimen
Description: Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants \< 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background regimen
Description: Background regimen may consist of the following ritonavir (RTV)-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants \< 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed.
Study: NCT04305990

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Demand-driven delivery method
Description: The gas delivery device is set to the demand-driven setting. Patients must inspire through their nose to trigger the flow of gas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Demand-driven delivery method
Description: The gas delivery device is set to the demand-driven setting. Patients must inspire through their nose to trigger the flow of gas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Free-flow delivery method
Description: The gas delivery device is set to a free-flow setting. Gas flows through the system at a rate determined by the operator. Standard flow rate is 6 liters per minute. Patients do not need to inspire through their nose to trigger the flow of gas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Free-flow delivery method
Description: The gas delivery device is set to a free-flow setting. Gas flows through the system at a rate determined by the operator. Standard flow rate is 6 liters per minute. Patients do not need to inspire through their nose to trigger the flow of gas.
Study: NCT04511637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form
Description: 15 mg as 1 x 15 mg film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form
Description: 15 mg as 1 x 15 mg film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY 59-7939, Xarelto) in film-coated form
Description: 15 mg as 1 x 15 mg film-coated tablet
Study: NCT03969901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMI/REL
Description: Age-based dosing:~* 12 to \<18 years, IMI 500 and REL 250 mg, IV infusion every 6 hours~* 2 to \<12 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~* 3 months to \<2 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours~* Birth to \<3 month, IMI 15 and REL 7.5 mg/kg, IV infusion every 8 hours NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention.
Study: NCT03398044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered to patients randomised into the active treatment arm, in order to determine the influence upon PONV incidence.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered to patients randomised into the control group arm.
Study: NCT03969901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: All active control medications will be chosen from a list of acceptable approved agents for each infection type (HABP or VABP, cIAI, and UTI) and will be given via IV infusion, per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.~NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention. All oral switch medications will be chosen from a list of acceptable approved agents.
Study: NCT00321984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 30 mg, capsules, orally, once daily for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
Study: NCT03640806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PHYSICAL ACTIVITY
Description: 3 fibromyactiv workshops per week during the first 6 months, or 72 sessions. Each workshop lasts 2 hours of physical activity.
Study: NCT00138151

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alpha-2b
Description: Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotretinoin
Description: Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days
Study: NCT01593683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological education program for nurses
Description: Approximately 4 weekly one-hour group sessions led by study clinicians and 1 optional individual session with a single study clinician.
Study: NCT02580916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SCQOLIT questionnaire
Description: Participants will be invited to complete the SCQOLIT and EQ-5D (used for comparison purposes, given its widespread use in other healthcare contexts in the UK) questionnaires \[Appendices C \& D) at:~1. baseline (after histological diagnosis of a NMSC is confirmed - both Groups)~2. 3 months - either by postal (Group 1) or face-to-face (Group 2) dependent on whether the patient is returning to the Dermatology clinic for routine follow-up~3. at 6-9 months in the dermatology clinic if the patient is deemed high risk (squamous cell carcinoma with high risk clinicopathological features as listed by the National British Association Dermatologists Multiprofessional Guidelines for management of SCC) (Group 2 only)
Study: NCT02936323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEN-221
Description: PEN-221 administered IV over 1 hour on an every 3-week cycle (21 days +/- 2 days) starting dose of 1 mg with each subsequent cohort increased starting dose level until MTD is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEN-221
Description: PEN-221 administered IV over 1 hour on an every 3-week cycle (21 days +/- 2 days) starting dose at recommended Phase 2a dose established in Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEN-221
Description: PEN-221 administered IV over 1 hour on an every 3-week cycle (21 days +/- 2 days) starting dose at recommended Phase 2a dose established in Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEN-221
Description: PEN-221 administered IV over 1 hour on an every 3-week cycle (21 days +/- 2 days) starting dose at recommended Phase 2a dose established in Phase 1.
Study: NCT03960814

Intervention type: DRUG
Intervention: Insulin detemir
Description: No treatment will be given to the patients in relation to this study. Patients have been included in this study because they have been treated with insulin glargine or detemir prior to study initiation (2004 - 2018) and according to routine clinical practice at that time. The decision to initiate treatment with commercially available insulin detemir and glargine has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Study: NCT00306189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100 mg AMG 162
Description: 100 mg AMG 162 (denosumab) SC every 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 60 mg AMG 162
Description: 60 mg AMG 162 (denosumab) SC every 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14 mg AMG 162
Description: 14 mg AMG 162 (denosumab) SC every 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo SC every 6 months
Study: NCT01088750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine sulfate

Intervention type: OTHER
Group type: OTHER
Intervention: watchful waiting

Intervention type: PROCEDURE
Group type: OTHER
Intervention: therapeutic conventional surgery
Study: NCT02044445

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oocyte retrieval will be performed 36 h or 38 h after hCG administration
Description: Oocyte retrieval will be performed 36 h or 38 h after hCG administration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oocyte retrieval will be performed 36 h or 38 h after hCG administration
Description: Oocyte retrieval will be performed 36 h or 38 h after hCG administration
Study: NCT01403311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Aminolevuline Acid
Description: 5-Aminolevuline Acid (ALA) at 30 mg/kg given orally 4 hours before surgery
Study: NCT02421471

Intervention type: DRUG
Intervention: Ingenol mebutate 0.015 percent or 0.05 percent gel
Description: Topical treatment with ingenol mebutate gel 0.015 percent or 0.05 percent gel of skin areas affected by AK
Study: NCT02083965

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Description: Administered as specified in the treatment arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Description: Administered as specified in the treatment arm.
Study: NCT03363997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estriol 0.125 mg/day
Description: Application of one vaginal ring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estriol 0.250 mg/day
Description: Application of one vaginal ring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estriol 0.500 mg/day
Description: Application of one vaginal ring
Study: NCT00354861

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B antigen (without alum) plus IMP321
Description: hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with IMP321

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: hepatitis B antigen alone (without alum)
Description: hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with physiological saline

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix B
Description: 20 µg hepatitis B antigen absorbed on alum
Study: NCT01275820

Intervention type: DIETARY_SUPPLEMENT
Intervention: Nutralin
Description: Food product to be taken 15 minutes prior to each of the three main meals of the day.
Study: NCT04346082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online mindfulness group
Description: Each weekly mindfulness session will last 45 to 60 minutes and will be held on an online platform (e.g. Zoom) via a livestream video. It will consist of short mindfulness exercise(s) of 10-30 minutes, including mindful tasting, mindful stretching, mindful walking, and body scan followed by group discussion to share, explore and make sense of the meditative experience. The intervention will be held in Cantonese.
Study: NCT00293033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEMA™
Description: BioDelivery Sciences International, Inc. (BDSI) has developed BioErodible MucoAdhesive (BEMA) Fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form. The BDSI product is a small soluble film that is placed against the mucosal membrane inside the mouth. The mucoadhesive polymers in the film readily adhere to the mucosal membrane (within 5 seconds) when moistened. The components of the film are water soluble, so the entire dosage form dissolves within 30 minutes of application.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BEMA™
Description: BioDelivery Sciences International, Inc. (BDSI) has developed BioErodible MucoAdhesive (BEMA) Fentanyl, an alternative product to OTFC that does not require the subject to continuously paint the inside of the mouth with the dosage form. The BDSI product is a small soluble film that is placed against the mucosal membrane inside the mouth. The mucoadhesive polymers in the film readily adhere to the mucosal membrane (within 5 seconds) when moistened. The components of the film are water soluble, so the entire dosage form dissolves within 30 minutes of application.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03118713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glimepiride
Description: oral
Study: NCT03950011

Intervention type: PROCEDURE
Intervention: Enhanced recovery after surgery program
Description: Enhanced Recovery After Surgery Programs (ERP) includes multimodal approaches of perioperative patient's clinical pathways designed to achieve early recovery after surgery and a decreased length of hospital stay (LOS).
Study: NCT00607815

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: CPT is a highly structured protocol in which the client learns the skill of recognizing and challenging dysfunctional cognitions, first about the worst traumatic event and then later with regard to the meaning of the events for current beliefs about self and others.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Therapy
Description: Present centered therapy is a supportive counseling model developed by Drs. Foa and Shea. The treatment is called present centered therapy to 1) emphasize the need to focus on the participant's current life and 2) to conceptualize the problems as being caused by PTSD, and in some cases they may have been present for a long period of time. The treatment makes a connection between PTSD and current problems thus making it a more realistic PTSD treatment and still allowing PCT to control for nonspecific therapeutic factors
Study: NCT00482027

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tgAAC09
Description: one or 2 doses of AAV-2 HIV vaccine (tgAAC09) at 3 dosage levels, dose escalation and dose optimization
Study: NCT01817244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care management
Description: 6-month care management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: care management
Description: 6-month care management
Study: NCT01640587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine+Artesunate
Description: One tablet of artesunate contains 40mg (Guilin Pharmaceutical Company, PRC). One tablet of mefloquine contains 250 mg mefloquine (Eloquine® (Medochemie Ltd., Cyprus) Standard three days regimen of artesunate-mefloquine given as 4mg/kg artesunate/day and 8 mg/kg of mefloquine/day on Days 0, 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine
Description: DHA-Piperaquine (Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China) One tablet contains 40mg of dihydroartemisinin and 320 mg piperaquine. A weight-based regimen containing 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
Study: NCT04686006

Intervention type: DRUG
Intervention: Potassium Iodide
Study: NCT04310657

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mNGS
Description: Metagenomics second generation sequencing technology
Study: NCT03131193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician
Description: Study primary health centers will be staffed with an additional physician

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician
Description: Study primary health centers will be staffed with an additional physician

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mid-level provider
Description: Study primary health centers will be staffed with an additional mid-level provider

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mid-level provider
Description: Study primary health centers will be staffed with an additional mid-level provider

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfer
Description: Study participants (who are pregnant women) will receive a cash transfer conditional upon: registering for and attending antenatal care in the study clinic, giving birth in the study clinic and completing a postnatal visit with the new infant

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfer
Description: Study participants (who are pregnant women) will receive a cash transfer conditional upon: registering for and attending antenatal care in the study clinic, giving birth in the study clinic and completing a postnatal visit with the new infant

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfer
Description: Study participants (who are pregnant women) will receive a cash transfer conditional upon: registering for and attending antenatal care in the study clinic, giving birth in the study clinic and completing a postnatal visit with the new infant
Study: NCT01628705

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Nutritional intervention
Description: The subjects were undergoing nutritional intervention was reduced by 500 kcal per day of habitual caloric intake.~The proportion of daily intake of macronutrient in the moderate-fat diet was: 30% fat (saturated fat \<7%, monounsaturated 10-15% and polyunsaturated 10%, respectively to total calories), 15% of protein, and 55% of carbohydrates. The dietary cholesterol was less than 200 mg/day, fiber intake was increased to 25 grams per day (50% soluble fiber).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea
Description: The patients drank secha green tea. Subjects of the INT group were instructed on how to prepare the green tea infusion. Each cup was prepared using 3g of dried green tea in 300ml of hot water (temperature 80°C)for 4 min. It was drunk fresh and without sugar. The treatment consisted of 2 cup/day of green tea, one in the morning and one at night. The amount of epigallocathechin-3-gallate was 498mg/day.
Study: NCT03431766

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: On control group A once the dental implants are inserted on both mandible or maxilla of the patient placebo (group A) would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 0.20% chlorhexidine gel
Description: On test group B once the dental implants are inserted on both mandible or maxilla of the patient a 0.20% chlorhexidine gel would be applied on the internal surface of the implants on all the surgical or prosthetic phases of the study.
Study: NCT03029442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab (Prolia)
Description: In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates. The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab (Prolia)
Description: In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates. The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Description: Identical Denosumab volume of normal saline

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Description: Identical Denosumab volume of normal saline
Study: NCT02853539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Subcutaneous injection of Denosumab
Study: NCT02848404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Categorical Language Fluency Smartphone Application
Description: 4 weeks' training
Study: NCT00190450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: graft intracerebral of foetal neurons
Description: graft intracerebral of foetal neurons

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: graft intracerebral of foetal neurons
Description: graft intracerebral of foetal neurons